Literature DB >> 20957479

Peak circulatory power as an indicator of clinical status in children after Fontan procedure.

Nitin Madan1, Lisa Beachler, Pantelis Konstantinopoulos, Sarah Worley, Zhiyuan Sun, Larry A Latson.   

Abstract

Peak circulatory power (CircP), a product of peak exercise oxygen uptake (VO(2)) and peak mean or systolic arterial blood pressure, has proved to be a strong predictor of poor outcome in adults with congenital heart disease. This study sought to compare CircP with other cardiopulmonary exercise (CPX) test variables and to assess whether CircP is superior in categorizing patients into well-functioning vs. poorly functioning at-risk groups in the pediatric population after a Fontan procedure. The CPX test reports of 50 patients were retrospectively reviewed after the Fontan procedure. The patients were divided into two groups. The well-functioning group included patients in New York Heart Association (NYHA) classes 1 and 2 (n = 36). The poorly functioning at-risk group included patients in NYHA classes 3 and 4 and those with significant indicators or outcomes of a poor prognosis (n = 14). The patients in the well-functioning group had significantly higher CircP values based on mean blood pressure (MBP) (P < 0.001), higher CircP values based on systolic blood pressure (SBP) (P < 0.001), and higher peak VO(2) (P = 0.004) than those in the poorly functioning at-risk group. At a cutoff value less than 2100.4 mmHg/mlO(2)/kg/min, CircP MBP had a sensitivity of 85% in categorizing children to the poorly functioning at-risk group. CircP correlated well with the clinical status of our patients. CircP and peak VO(2) did not differ significantly in ability to identify poorly functioning patients. Further prospective analysis is needed to assess whether CircP can serve as a prognostic marker for the pediatric population after Fontan procedure.

Entities:  

Mesh:

Year:  2010        PMID: 20957479     DOI: 10.1007/s00246-010-9799-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  Exercise capacity in pediatric heart transplant candidates: is there any role for the 14 ml/kg/min guideline?

Authors:  B B Das; A L Taylor; M M Boucek; R W Wolfe; A T Yetman
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

2.  Comparison and relation of indirect and direct dynamic indexes of cardiac pumping capacity in chronic heart failure.

Authors:  Simon G Williams; Bing-H Tzeng; Diane Barker; Lip-Bun Tan
Journal:  Am J Cardiol       Date:  2005-09-01       Impact factor: 2.778

3.  A non-invasively determined surrogate of cardiac power ('circulatory power') at peak exercise is a powerful prognostic factor in chronic heart failure.

Authors:  A Cohen-Solal; J Y Tabet; D Logeart; P Bourgoin; M Tokmakova; M Dahan
Journal:  Eur Heart J       Date:  2002-05       Impact factor: 29.983

4.  Scaling for the VO2-to-body size relationship among children and adults.

Authors:  D M Rogers; B L Olson; J H Wilmore
Journal:  J Appl Physiol (1985)       Date:  1995-09

5.  Comparison of the long-term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure.

Authors:  A Cohen-Solal; P Barnier; F Pessione; P Seknadji; D Logeart; T Laperche; R Gourgon
Journal:  Heart       Date:  1997-12       Impact factor: 5.994

6.  Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation.

Authors:  N Osada; B R Chaitman; L W Miller; D Yip; M B Cishek; T L Wolford; T J Donohue
Journal:  J Am Coll Cardiol       Date:  1998-03-01       Impact factor: 24.094

7.  Strong and independent prognostic value of peak circulatory power in adults with congenital heart disease.

Authors:  Alessandro Giardini; Salvatore Specchia; Emanuela Berton; Diego Sangiorgi; Gloria Coutsoumbas; Gaetano Gargiulo; Guido Oppido; Marco Bonvicini; Fernando M Picchio
Journal:  Am Heart J       Date:  2007-09       Impact factor: 4.749

8.  Clinical outcome 5 to 18 years after the Fontan operation performed on children younger than 5 years.

Authors:  Daniëlle Robbers-Visser; Livia Kapusta; Lennie van Osch-Gevers; Jan L M Strengers; Eric Boersma; Yolanda B de Rijke; Frans Boomsma; Ad J J C Bogers; Willem A Helbing
Journal:  J Thorac Cardiovasc Surg       Date:  2009-02-23       Impact factor: 5.209

9.  A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation.

Authors:  Stephen M Paridon; Paul D Mitchell; Steven D Colan; Richard V Williams; Andrew Blaufox; Jennifer S Li; Renee Margossian; Seema Mital; Jennifer Russell; Jonathan Rhodes
Journal:  J Am Coll Cardiol       Date:  2008-07-08       Impact factor: 24.094

10.  Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy.

Authors:  A M Stelken; L T Younis; S H Jennison; D D Miller; L W Miller; L J Shaw; D Kargl; B R Chaitman
Journal:  J Am Coll Cardiol       Date:  1996-02       Impact factor: 24.094

View more
  3 in total

1.  Circulatory and Ventilatory Power: Characterization in Patients with Coronary Artery Disease.

Authors:  Viviane Castello-Simões; Vinicius Minatel; Marlus Karsten; Rodrigo Polaquini Simões; Natália Maria Perseguini; Juliana Cristina Milan; Ross Arena; Laura Maria Tomazi Neves; Audrey Borghi-Silva; Aparecida Maria Catai
Journal:  Arq Bras Cardiol       Date:  2015-05-05       Impact factor: 2.000

2.  Comparison of the Degree of Exercise Tolerance in Children After Surgical Treatment of Complex Cardiac Defects, Assessed Using Ergospirometry and the Level of Brain Natriuretic Peptide.

Authors:  Boguslaw Mazurek; Leslaw Szydlowski; Magdalena Mazurek; Grazyna Markiewicz-Loskot; Jacek Pajak; Aleksandra Morka
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

3.  The "Super-Fontan" Phenotype: Characterizing Factors Associated With High Physical Performance.

Authors:  Derek L Tran; David S Celermajer; Julian Ayer; Leeanne Grigg; Carley Clendenning; Tim Hornung; Robert Justo; Glen M Davis; Yves d'Udekem; Rachael Cordina
Journal:  Front Cardiovasc Med       Date:  2021-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.